Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by BlaineBorgon Jul 06, 2021 4:45pm
82 Views
Post# 33500465

RE:RE:RE:RE:RE:RE:6 Fold Dilution To Chase After COVID-19. End Of Story.

RE:RE:RE:RE:RE:RE:6 Fold Dilution To Chase After COVID-19. End Of Story.You call what I do whatever you want. You simply are a nuts hanger on. As I've said you are talking about something you know nothing about. I guess that's your new outlandish theme here now. The clinical trial was last 50% enrolled. Dunce cap CEO says it's slow enrollment. I believe it and also believe he knew that would be the case from the beginning with only having a handful of locations to recruit. It's literally a needle in a haystack how they have gone about recruitment halfway around the world. Bellus Health stayed right here in North America and opened 100+ clinical trial sites to get their second CC study done ASAP. That's real leadership! Moreau says he saved 600k in taxes by doing that. The end result is massive dilution as we wait and wait for a days readout. The cost to shareholders and the reputation of the company is being calculated now and into the future. Moreau is driving the company further down with dumb decisions he blames on others. No way can anyone say it's been a colossal screw up. Recruitment remains the problem. Of the CEO has inside info about the current status of patient outcome, it would be wise for him to not pump a bunch of hot air about a positive outcome. So far he's pumped out the IL-6 data from the COVID trial as positive news for the IPF study so he's already begun traveling down that pump road as he likely knew the COVID-19 study was dead in the water as stated by Mackie Research 3 months ago. Yet the story continued to the bitter end. IPF/CC is the last stop on this pennyland bus. I'm one whose not going to further waste time entertaining your wild speculative theories here. Have fun but just know I've put you on Ig-snore. Zzzzz BB
<< Previous
Bullboard Posts
Next >>